Antibody Inhibition of S. aureus Mn 2+ Import

SUPPLEMENTAL EXPERIMENTAL PROCEDURES FACS analysis
Methicillin-resistant S. aureus strain SF8300 was used as the WT strain and served as the parent for all subsequent mutants. The mntC null mutant was constructed as described previously by inactivating the mntC gene by specifically replacing Leu8 and Leu12 with stop codons (Diep et al., 2014) . To minimize non-specific binding of antibody to the bacteria, all strains were also spa null. For some experiments, the strain was also tagO null, as indicated in the Results. The spa and tagO null mutations were generated by insertion of an intron using the Targetron method (Sigma). S. aureus cells were grown overnight at 37ºC in Brain Heart Infusion media, then back diluted and grown to mid-log phase. Bacteria were immunolabeled with FabC1 or an isotype control Fab as the primary label, followed by secondary labeling with Alexa-fluor 488 conjugated anti-human Fab. Binding of FabC1 to bacteria was determined by flow cytometry using a FACSAria cell sorter (BD Biosciences, San Jose CA) and data analysis was performed using FlowJo software (Tree Star Inc, Ashland, OR). The isotype control Fab was used to set the negative gate and defined as cells that did not shift. This gate was applied to all additional samples and cells that were found outside of the negative gate were designated as those with a positive shift.
S. aureus ROS survival assay
The methicillin-resistant S. aureus SF8300 WT and mntC null strains were as described above. In some experiments (indicated in Results), the aforementioned spa null mutation was also introduced. Methyl viologen (MV) was used as a ROS generator. For ROS survival assays, cells were grown overnight in chelex®-treated (Sigma-Aldrich, St. Louis, MO) Brain Heart Infusion media followed by back dilution and further growth to mid-log phase. Log phase cells were then aliquotted into 96 well plates at a concentration of 1,000 colony-forming units (CFU) per well. for mntC null mutant samples, concentrations determined empirically to be optimal for sub-lethal effects of MV. Cells were then incubated overnight at 37°C followed by serial dilution for enumeration of surviving CFU. Analyses were performed in triplicate and reported with standard deviations.
A similar assay was used to test the effect of mutations in MntC on the survival of S. aureus under conditions of ROS generation. The mntC gene encoding each mutation was added back to an mntC null mutant on a replicating plasmid, pMK4 (Sullivan et al., 1984) . The complementation vector for the mntC null mutant encompassed 104 base pairs of the promoter region and the entire mntABC operon.
Expression of the mutants in S. aureus to levels indistinguishable from WT MntC was confirmed by
Western blotting with rabbit polyclonal sera raised against purified MntC. WT and mntC null mutant carrying empty plasmids were used as control strains to compare survival in the presence of MV across all strains. Cells were grown and exposed to 1 mM MV, as outlined previously. Survival was determined by plating for CFUs after incubation at 37 °C for 16 hr.
Crystallization, data collection and structure determination
For the isolated MntC structure (Zn(II)-MntC), protein was purified from cells grown in LB media, as outlined in the Experimental Procedures. ICP-MS analyses (see below) indicated this protein was predominantly Zn(II)-loaded (Table S1 , Sample 1a). For the MntC-FabC1 complex structure, MntC was purified from cells grown in M9 minimal media. ICP-MS analyses indicated that upon EDTA treatment, the majority of this protein was metal-free (Table S1 , Sample 1b). This protein was mixed with excess FabC1 and the MntC-FabC1 complex was isolated using size exclusion chromatography in buffer containing 25 mM Tris pH 8.0, 150 mM NaCl and 20 mM EDTA. The 20 mM EDTA was only present in the MntC-FabC1 complex sample and this treatment proved necessary to obtain crystals of the complex.
MntC alone and MntC:FabC1 crystals were obtained using hanging drop vapor diffusion at 20ºC with 500 µl of reservoir solution and 2 µl drops containing equal volumes of protein (13 mg/ml) and reservoir. For
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MntC alone, crystals of 100 µm x 50 µm x 20 µm size formed after 4 days with a reservoir solution containing 30% PEG 1,500. These were cryoprotected in 50% PEG 1,500 and data of 1.17 Å resolution were collected at beamline 11-1 of the Stanford Synchrotron Radiation Lightsource (Menlo Park, CA).
MntC:FabC1 crystals of 100 µm x 100 µm x 10 µm size grew in 10 days with a reservoir solution containing 0.1 M Tris pH 8.5, 20% PEG 10,000 and 0.7% 1-butanol. A 2.7 Å resolution x-ray diffraction dataset was collected at the 12-2 beamline of the Stanford Synchrotron Radiation Lightsource (Menlo Park, CA). Crystallographic data were processed using HKL2000 (Otwinowski and Minor, 1997) . restraints for refinement were generated using Phenix. These parameters were then refined against the data where a generous potential deviation of 5 degrees was allowed for all bond angles and 0.2 Å for the bond lengths. For the MntC-FabC1 complex structure, our 1.17 Å resolution MntC structure and the Fab fragment from the structure of Herceptin (PDB code: 1FVE) (Eigenbrot et al., 1993) were used as search models. The model was then built using COOT (Emsley and Cowtan, 2004 ) and adjusted to F obs -F calc and 2F obs -F calc maps amid cycles of standard positional & thermal factor refinement and density modification in PHENIX (Adams et al., 2010) to generate the final models. Pymol (Schrodinger, 2010) was used to render the crystal structures. Data collection and refinement statistics are summarized in Table 1 .
Solution NMR Experiments
All two-dimensional 15 N-1 H TROSY NMR experiments were performed on a Bruker Avance 600 MHz or 900 MHz four-channel NMR system equipped with an x,y,z axis PFG 5 mm TCI cryoprobe at 298 K.
Samples for NMR were prepared using an appropriate amount of protein (0.1 -0.7 mM), in Buffer A. All NMR spectra were processed and analyzed using either NMRPipe (Delaglio et al., 1995) or TopSpin 3.0 (Bruker) and Sparky (Kneller and Kuntz, 1993) .
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Refolding of MntC
100% Zn(II)-bound MntC was generated by simply incubating the purified protein overnight with an excess of Zn(II) ion (Table S1 , Sample 2a). Predominantly Mn(II)-bound and apo-states of MntC were prepared by denaturation and refolding, essentially as described previously (Lim et al., 2008) . Briefly, purified recombinant MntC was denatured during dialysis using buffer A (25 mM HEPES, 100 mM NaCl, pH 7.5) containing 6 M guanidine-HCl, a 2-fold molar excess of TPEN (Sigma Aldrich) and 10 mM EDTA, for 3 hours at 25°C, followed by further dialysis overnight at 4°C. The denatured protein was then refolded at 4ºC through serial dialysis. To generate metal-free apo-MntC, the order of dialysis buffers was buffer-A containing (i) 6 M urea and 10 mM EDTA for 4 hours, (ii) 2 M urea, 10 mM EDTA for 4 hours, and (iii) 10 mM EDTA overnight. To generate predominantly Mn(II)-bound MntC, the denatured protein was similarly refolded, except that 10 mM EDTA was replaced with 10 mM MnCl 2 in all buffers. The final metal content of each sample was assessed by ICP-MS (detailed below). The refolded Mn(II)-MntC was determined to be >90% Mn(II)-loaded (Table S1 , Sample 3a) whereas refolded apo-MntC was ~95% metal-free (Table S1 , Sample 4a).
ICP-MS analyses
The type and concentration of metal ions in MntC samples were determined by ICP-MS. Reagents used for ICP-MS studies were nitric acid (EMD grade, EMD, La Jolla, CA), Ultrex II ultrapure nitric acid (JT Baker, Phillipsburg, NJ), NIST traceable certified ICP standards (EMD, La Jolla, CA; VHG Labs, Manchester, NH, Ultra Scientific, Kingstown, RI), and argon, nitrogen, and CCT (7% hydrogen in helium) gasses (Praxair, Danbury, CT). Analytical solvent was prepared using 18.2 M-ohm-cm water to dilute concentrated EMD nitric acid to 5% v/v.
The apo and metal-loaded MntC protein samples used for ICP-MS analyses were generated as described in the Experimental Procedures. For the MntC-FabC1 complex samples, FabC1 was added at a 1.2 molar excess and the proteins were incubated at 22ºC for 16 hours. The samples were then extensively The protein samples required additional pretreatment prior to ICP-MS analysis to maintain solubility in 5% nitric acid analytical solvent. Protein samples were first digested with concentrated Ultrex II nitric acid (0.5 mL sample:0.5 mL acid) in a 14 mL culture tube, followed by heating at 70 ºC for 30 min.
Digested samples were then diluted 10x by the addition of 9 mL of 5% nitric acid for a final sample dilution factor of 20-fold. ICP-MS measurements were then made with a Thermo Scientific X series II ICP-MS instrument controlled by PlasmaLab software (Thermo Scientific, Franklin, MA), fitted with a PC3-R-F Pelletier cooled spray chamber cooled to 2° C and a microflow nebulizer (Elemental Scientific, Omaha, NE). Typical operating conditions were: RF power = 1400 W, nebulizer Ar flow rate = 0.9 L min -1 , cool Ar flow rate = 14 L min -1 and auxiliary Ar flow rate = 0.7 min -1 . Samples were introduced with a peristaltic pump using a flow rate of 0.8 mL/min. Dwell times ranged from 500 ms for Al to 20 milliseconds for the higher mass metals ( 66 Zn and above). Data analyses were performed by PlasmaLab software. Unknown sample values were calculated by comparison to a blank corrected standard curve prepared from certified ICP standards in the same 5% nitric acid analytical solvent. Internal standards ( 45 Sc, 103 Rh, and 159 Tb) were also added in-line during each run, and signal drift correction was performed based on recovery of internal standards, with interpolation between the internal standard mass values.
Standard interference equations were used to correct for isobaric interferences (Vogl, 2005) . All ICP-MS data were collected in parts-per-billion (ppb) and then converted to percentage (%) of the total protein concentration. Any metal-ion below the detection limit (i.e. < 50 ppb) was excluded from the analysis.
